{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:18:51Z","timestamp":1793287131735,"version":"4.5.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Renin Angiotensin Aldosterone Syst"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>This study was performed to address the pathological roles of the skeletal renin-angiotensin system (RAS) in type 1 diabetes-induced osteoporosis and the effects of the angiotensin II type 1 receptor blocker losartan on bones in diabetic mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods:<\/jats:title>\n                    <jats:p>Bone histomorphology was detected by H&amp;E staining, Safranin O staining and X-ray radiography. Micro-CT was performed for the analysis of bone parameters. Gene and protein expression were determined by RT-PCR and immunoblotting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Type 1 diabetic mice displayed osteopenia phenotype, and losartan treatment had no osteoprotective effects on diabetic mice as shown by the reduction of bone mineral density and microarchitectural parameters at the proximal metaphysis of the tibia. The mRNA expression of AGT, renin receptor and ACE, and protein expression of renin and AT1R were markedly up-regulated in the bones of vehicle-treated diabetic mice compared to those of non-diabetic mice. The treatment with losartan further significantly increased the expression of AGT, renin, angiotensin II and AT1R, and reduced the expression of AT2R receptor as compared to those of diabetic mice.<\/jats:p>\n                    <jats:sec>\n                      <jats:title>Conclusion:<\/jats:title>\n                      <jats:p>Local bone RAS functionally played a role in the development of type 1 diabetic osteoporosis, and losartan had no bone-sparing function in diabetes mice because of enhance skeletal RAS activity.<\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1177\/1470320312471229","type":"journal-article","created":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T01:54:53Z","timestamp":1357178093000},"page":"218-227","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Effects of angiotensin II type 1 receptor blocker on bones in mice with type 1 diabetes induced by streptozotocin"],"prefix":"10.1177","volume":"15","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[{"name":"Center for Systems Biomedical Sciences, University of Shanghai for Science and Technology, People\u2019s Republic of China"},{"name":"Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, People\u2019s Republic of China"},{"name":"School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Yue","family":"Diao","sequence":"additional","affiliation":[{"name":"Center for Systems Biomedical Sciences, University of Shanghai for Science and Technology, People\u2019s Republic of China"},{"name":"School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa-Sa","family":"Gu","sequence":"additional","affiliation":[{"name":"Center for Systems Biomedical Sciences, University of Shanghai for Science and Technology, People\u2019s Republic of China"},{"name":"School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Yan","family":"Wu","sequence":"additional","affiliation":[{"name":"Center for Systems Biomedical Sciences, University of Shanghai for Science and Technology, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoseph A","family":"Gebru","sequence":"additional","affiliation":[{"name":"Center for Systems Biomedical Sciences, University of Shanghai for Science and Technology, People\u2019s Republic of China"},{"name":"School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Norman Bethune First Hospital of Jilin University, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Ran","sequence":"additional","affiliation":[{"name":"Center for Systems Biomedical Sciences, University of Shanghai for Science and Technology, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Sau","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,9]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2011.04.004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1295-1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0803751105"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00247.2009"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1619-x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32834bbb4d"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081006"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M807610200"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-098954"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.5914"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1271\/bbb.120123"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00651.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070510"},{"key":"e_1_3_2_15_2","first-page":"178","article-title":"Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients","volume":"107","author":"Vijan SG","year":"2009","unstructured":"Vijan SG. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients. J Indian Med Assoc 2009; 107: 178\u2013182.","journal-title":"J Indian Med Assoc"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.10.009"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2009.189"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2009.186"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.22"},{"key":"e_1_3_2_20_2","first-page":"749","article-title":"Differential clinical profile of candesartan compared to other angiotensin receptor blockers","volume":"7","author":"Cernes R","year":"2011","unstructured":"Cernes R, Mashavi M, Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc Health Risk Manag 2011; 7: 749\u2013759.","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017437"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-008-9490-0"},{"key":"e_1_3_2_23_2","first-page":"750","article-title":"Inhibition of renin: An updated review of the development of renin inhibitors","volume":"8","author":"Li YC","year":"2009","unstructured":"Li YC. Inhibition of renin: An updated review of the development of renin inhibitors. Curr Opin Investig Drugs 2009; 8: 750\u2013757.","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1404-1"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-011-0534-x"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2010.79"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2010.155"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)01049-8"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.501"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/me.2004-0536"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.09.011"},{"key":"e_1_3_2_32_2","first-page":"692","article-title":"Evolution of the bone mass of hypertense menopausal women in treatment with fosinopril","volume":"127","author":"Garc\u00eda-Tesal A","year":"2006","unstructured":"Garc\u00eda-Tesal A, Monz\u00f3 A, Rabanaque G, et al. Evolution of the bone mass of hypertense menopausal women in treatment with fosinopril. Med Clin (Barc) 2006; 127: 692\u2013694.","journal-title":"Med Clin (Barc)"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-011-1831-7"}],"container-title":["Journal of the Renin-Angiotensin-Aldosterone System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1470320312471229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1470320312471229","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1470320312471229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:38:37Z","timestamp":1777509517000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1470320312471229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1177\/1470320312471229"],"URL":"https:\/\/doi.org\/10.1177\/1470320312471229","relation":{},"ISSN":["1470-3203","1752-8976"],"issn-type":[{"value":"1470-3203","type":"print"},{"value":"1752-8976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}